Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 5,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $16.49, for a total value of $82,450.00. Following the sale, the chief executive officer now directly owns 972,892 shares in the company, valued at $16,042,989.08. This trade represents a 0.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Samuel Kintz also recently made the following trade(s):

• On Thursday, May 1st, Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.08, for a total value of $107,026.40.
• On Thursday, April 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.42, for a total value of $82,100.00.
• On Monday, March 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.83, for a total value of $260,375.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $16.93 on Thursday. The business’s fifty day moving average price is $18.62 and its two-hundred day moving average price is $21.52. The stock has a market cap of $830.74 million, a PE ratio of -8.91 and a beta of 1.07. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. grew its stake in Enliven Therapeutics by 3.5% in the 4th quarter. Invesco Ltd. now owns 15,072 shares of the company’s stock worth $339,000 after acquiring an additional 508 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock valued at $451,000 after purchasing an additional 718 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Enliven Therapeutics by 14.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock valued at $233,000 after purchasing an additional 1,275 shares during the last quarter. Finally, MetLife Investment Management LLC increased its stake in Enliven Therapeutics by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 21,746 shares of the company’s stock valued at $489,000 after purchasing an additional 1,285 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ELVN shares. HC Wainwright lifted their price target on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, May 15th. Jones Trading dropped their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 16th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Enliven Therapeutics currently has a consensus rating of “Buy” and an average price target of $37.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.